Study to Compare the Effectiveness and Safety of Golcadomide Plus R-CHOP vs Placebo Plus R-CHOP in Participants With Previously Untreated High-risk Large B-cell Lymphoma (NCT06356129)
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study Comparing the Efficacy and Safety of Golcadomide Plus R-CHOP Chemotherapy vs Placebo Plus R-CHOP Chemotherapy in Participants With Previously Untreated High-risk Large B-cell Lymphoma (GOLSEEK-1)
🩺 Plain-English Summary (8th-Grade Level)
The purpose of this study is to compare the effectiveness and safety of golcadomide in combination with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) chemotherapy vs placebo in combination with R-CHOP chemotherapy in participants with previously untreated high-risk large B-cell lymphoma (LBCL).
Who can join: Review the eligibility criteria below.
Location: Local Institution - 0014 — Mobile, Alabama
Age range: 18 Years to 80 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (325 Sites)
Showing the first 25 of 325 sites.
- Local Institution - 0014 — Mobile, Alabama
- Local Institution - 0477 — Anchorage, Alaska
- Local Institution - 0452 — Phoenix, Arizona
- Local Institution - 0342 — San Francisco, California
- Local Institution - 0497 — Fort Myers, Florida
- Local Institution - 0287 — Jacksonville, Florida
- Local Institution - 0415 — Margate, Florida
- Local Institution - 0045 — Miami Beach, Florida
- Local Institution - 0012 — Pensacola, Florida
- Local Institution - 0502 — St. Petersburg, Florida
- Local Institution - 0414 — Tampa, Florida
- Local Institution - 0192 — West Palm Beach, Florida
- Local Institution - 0485 — Weston, Florida
- Local Institution - 0515 — Atlanta, Georgia
- Local Institution - 0303 — Atlanta, Georgia
- Local Institution - 0182 — Chicago, Illinois
- Local Institution - 0048 — Skokie, Illinois
- Local Institution - 0461 — Waukee, Iowa
- Local Institution - 0031 — Westwood, Kansas
- Local Institution - 0436 — Edgewood, Kentucky
- Local Institution - 0408 — Baton Rouge, Louisiana
- Local Institution - 0478 — Ann Arbor, Michigan
- Local Institution - 0067 — Minneapolis, Minnesota
- Local Institution - 0203 — Rochester, Minnesota
- Local Institution - 0437 — Kansas City, Missouri
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Large B-cell Lymphoma
- An Open-Label Study Comparing Glofitamab and Polatuzumab Vedotin + Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone Versus Pola-R-CHP in Previously Untreated Patients With Large B-Cell Lymphoma — Anchorage, Alaska
- Mosunetuzumab in Combination With Platinum-Based Salvage Chemotherapy in Patients With Relapsed/Refractory Aggressive B Cell Lymphoma — St Louis, Missouri
- Golcadomide With Pemetrexed, Rituximab, and Dexamethasone for Relapsed and Refractory CNS Lymphomas — Cleveland, Ohio
- Phase 2 Trial of CD70.CAR NK Cells for Patients With Primary Refractory or Early Relapsed Diffuse Large B-Cell Lymphoma and Hodgkin Lymphoma — Houston, Texas
- CAR-T Followed by Bispecific Antibodies — Omaha, Nebraska
Explore by condition: All Large B-cell Lymphoma clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Review the official NIH record below to find the coordinating site.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.